WO2001034566A3 - Inhibiteurs de la protease - Google Patents

Inhibiteurs de la protease Download PDF

Info

Publication number
WO2001034566A3
WO2001034566A3 PCT/US2000/030682 US0030682W WO0134566A3 WO 2001034566 A3 WO2001034566 A3 WO 2001034566A3 US 0030682 W US0030682 W US 0030682W WO 0134566 A3 WO0134566 A3 WO 0134566A3
Authority
WO
WIPO (PCT)
Prior art keywords
protease inhibitors
solvate
hydrate
inhibition
inhibitor
Prior art date
Application number
PCT/US2000/030682
Other languages
English (en)
Other versions
WO2001034566A2 (fr
Inventor
Robert W Marquis Jr
Daniel Frank Veber
Original Assignee
Smithkline Beecham Corp
Robert W Marquis Jr
Daniel Frank Veber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Robert W Marquis Jr, Daniel Frank Veber filed Critical Smithkline Beecham Corp
Priority to JP2001536515A priority Critical patent/JP2003533432A/ja
Priority to EP00977056A priority patent/EP1351930A4/fr
Priority to AU14747/01A priority patent/AU1474701A/en
Publication of WO2001034566A2 publication Critical patent/WO2001034566A2/fr
Publication of WO2001034566A3 publication Critical patent/WO2001034566A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Cette invention concerne un composé de la formule (I), ou un sel, un hydrate ou un solvate pharmaceutiquement acceptable dudit composé, lequel est un inhibiteur des cystéines protéases, notamment la cathepsine K. Ce composé est utile pour le traitement de maladies dans lesquelles l'inhibition de la perte osseuse ou de la dégradation cartilagineuse est un facteur.
PCT/US2000/030682 1999-11-10 2000-11-08 Inhibiteurs de la protease WO2001034566A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2001536515A JP2003533432A (ja) 1999-11-10 2000-11-08 プロテア−ゼ阻害剤
EP00977056A EP1351930A4 (fr) 1999-11-10 2000-11-08 Inhibiteurs de la protease
AU14747/01A AU1474701A (en) 1999-11-10 2000-11-08 Protease inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16456199P 1999-11-10 1999-11-10
US60/164,561 1999-11-10

Publications (2)

Publication Number Publication Date
WO2001034566A2 WO2001034566A2 (fr) 2001-05-17
WO2001034566A3 true WO2001034566A3 (fr) 2003-07-31

Family

ID=22595065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030682 WO2001034566A2 (fr) 1999-11-10 2000-11-08 Inhibiteurs de la protease

Country Status (4)

Country Link
EP (1) EP1351930A4 (fr)
JP (1) JP2003533432A (fr)
AU (1) AU1474701A (fr)
WO (1) WO2001034566A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20012277A3 (cs) * 1998-12-23 2001-11-14 Smithkline Beecham Corporation Inhibitory proteázy
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
WO2001034156A1 (fr) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Inhibiteurs de protease
EP1232154A4 (fr) 1999-11-10 2004-06-23 Smithkline Beecham Corp Inhibiteurs de protease
US6596715B1 (en) 1999-11-10 2003-07-22 Smithkline Beecham Corporation Protease inhibitors
CA2404206A1 (fr) 2000-03-21 2001-09-27 Smithkline Beecham Corporation Inhibiteur de proteinase
CO5280093A1 (es) * 2000-04-18 2003-05-30 Smithkline Beecham Corp Metodos de tratamiento
CN105288305A (zh) * 2015-11-30 2016-02-03 延欣虹 一种治疗口腔上火及牙龈肿痛的药物组合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038687A1 (fr) * 1998-12-23 2000-07-06 Smithkline Beecham Corporation Inhibiteurs de proteases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2285A1 (fr) * 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038687A1 (fr) * 1998-12-23 2000-07-06 Smithkline Beecham Corporation Inhibiteurs de proteases

Also Published As

Publication number Publication date
JP2003533432A (ja) 2003-11-11
AU1474701A (en) 2001-06-06
EP1351930A2 (fr) 2003-10-15
EP1351930A4 (fr) 2004-09-15
WO2001034566A2 (fr) 2001-05-17

Similar Documents

Publication Publication Date Title
WO2002069901A3 (fr) Inhibiteurs de cathepsines de la cysteine protease
WO2003075836A3 (fr) Inhibiteurs de cathepsine cysteine protease
MXPA04001930A (es) Inhibidores de proteasa de cisteina con estructura de 2-ciano-4amino-pirimidina y actividad inhibidora de catepsina k para el tratamiento de inflaciones y otras enfermedades.
CA2458684A1 (fr) Pyrrolopyrimides en tant qu'agents d'inhibition de cysteine proteases
AU2003243095A1 (en) New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
WO2001034565A3 (fr) Inhibiteurs de protease
MXPA03006224A (es) Inhibidores de cruzipaina y otras proteasas de cisteina.
WO2004031145A3 (fr) Diaminoalkyle contenant du lactame, acides amines beta, acides amines alpha et leurs derives utilises en tant qu'inhibiteurs du facteur xa
WO2001034566A3 (fr) Inhibiteurs de la protease
AR021241A1 (es) Inhibidores de proteasas
AU2002348473A1 (en) Nitrogen heterocycle inhibitors of aspartyl protease
HK1053121A1 (en) New amidino derivatives and their use as thrombin inhibitors
WO2002070517A3 (fr) Inhibiteurs de cysteine protease de type cathepsine
WO2004108892A3 (fr) $g(a)-aminoacides, $g(b)-aminoacides, diaminoalkyle contenant 1,1-disubstitue cycloalkyle, glycinamidyle, sulfonyl-amidino-, et tetrahydropyrimidinyle et leurs derives utilises comme inhibiteurs du facteur xa
MY132033A (en) New mandelic acid derivatives and their use as thrombin inhibitors
IL160068A0 (en) Mew mandelic acid derivatives and their use as thrombin inhibitors
WO2001079162A3 (fr) Inhibiteurs de la famille ice/ced-3 de cysteines proteases
ECSP993018A (es) Nuevos inhibidores de proteasas, particularmente inhibidores de cisteina y serina proteasas
WO2002023784A3 (fr) Inhibiteurs de la cysteine protease
AU2002348212A8 (en) Protease inhibitors of the coagulation cascade isolated from dysidea sponges
MY139221A (en) Cathepsin cysteine protease inhibitors
UY25369A1 (es) Procedimiento para preparar inhibidores de proteasa
ECSP993211A (es) Inhibidores de proteasas vi

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 536515

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10129648

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000977056

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000977056

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000977056

Country of ref document: EP